<DOC>
	<DOCNO>NCT01195480</DOCNO>
	<brief_summary>The aim clinical trial evaluate feasibility , safety biological effect adoptive transfer CD19ζ chimaeric receptor transduce donor-derived EBV-specific cytotoxic T-lymphocytes ( EBV-CTL ) patient high-risk relapsed B cell precursor ALL allogeneic Haematopoietic Stem Cell Transplantation ( HSCT ) .</brief_summary>
	<brief_title>CD19-CAR Immunotherapy Childhood Acute Lymphoblastic Leukemia ( ALL )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>Inclusion Criteria Preemptive arm Children ( 18 year young ) CD19+ precursor B cell ALL fulfil one follow criterion undergo allogeneic stem cell transplant EBVseropositive donor : In first remission , least one follow criterion meet : ( 9 ; 22 ) MRD positive ( BCRABL/ABL ratio &gt; 0.01 % ) HR3 block EsPhALL preHSCT Infant ALL age &lt; 6 month diagnosis MLL gene rearrangement either present wcc &gt; 300 x 10^9/L poor steroid early response ( i.e circulate blast count &gt; 1x10^9/L follow 7 day steroid prephase Interfant 06 ) Resistant disease ( &gt; 30 % blast end induction treatment day 2833 ) subsequent morphological CR High level bone marrow MRD ( &gt; 1 1000 ) week 12 ALLBFM 2000/AIEOP BFM ALL 2009/EORTC 58951 protocol , week 1215 FRALLE A week 14 UKALL2011 Relapsed patient least one follow criterion meet : Very early ( &lt; 18 month diagnosis ) bone marrow extramedullary relapse second CR Early ( within 6 month finish therapy ) isolate bone marrow relapse bone marrow MRD &gt; 1 100 day 35 reinduction second CR Early ( within 6 month finish therapy ) bone marrow combine relapse high level bone marrow MRD ( &gt; 1 1000 ) end consolidation therapy ( week 1213 UKALL R3/INTREALL COOPRALL protocol , prior protocol M BFM relapse protocol ( ALLREZ BFM 2002 ) Protocol IIIDA AIEOP LLA Rec 2003 ) Any relapse infant Philadelphiapositive ALL morphological complete remission Any patient transplant 3rd great CR These patient high ( &gt; 50 % ) risk relapse monitor evidence MRD bone marrow aspirate ( monthly month 16 , 6 weekly month 7.512 post HSCT ) first year posttransplant . Patients become MRD +ve marrow level minimum 5 x 104 ( BCRABL/ABL ratio 0.05 % Ph+ve ALL patient IgH MRD marker ) morphological remission ( &lt; 5 % blast BM ) eligible treat preemptively CD19ζ transduce CTL Prophylaxis arm Additionally , patient ( ≤ 18 year ) ALL relapse bone marrow ( isolated combine ) myeloablative allogeneic HSCT achieve morphological remission reinduction candidate second HSCT one participate centre eligible receive CD19ζ transduce CTL prophylactically Stem cell donor must EBV seropositive HLAmatched ( 8/8 HLA A , B , C DR medium resolution type ) single antigenic/allelic ( 7/8 ) mismatch recipient A life expectancy least 12 week Karnofsky score &gt; 60 % &gt; 10 year old Lansky performance score &gt; 60 ≤ 10 year old Patients must transduce donorderived EBVspecific CTLs 15 % high expression CD19ζ determine flowcytometry meet specify release criterion Informed write consent indicate patient aware research study tell possible benefit toxic side effect Exclusion Criteria Patients CD19 negative precursor B cell ALL EBV seronegative &gt; single antigenic/allelic HLAmismatched donor Active acute GVHD overall Grade 2 high significant chronic GVHD require systemic steroid time schedule infusion transduce CTL exclude patient GVHDfree steroid Preexisting severe lung disease ( FEV1 FVC &lt; 50 % predict ) preHSCT oxygen requirement &gt; 28 % O2 supplementation active pulmonary infiltrates chest Xray time schedule transduce CTL infusion Serum bilirubin &gt; 3 time upper limit normal AST ALT &gt; 5 time upper limit normal Serum creatinine &gt; 3 time upper limit normal Active severe intercurrent infection time transduce CTL infusion ( present consult Chief investigator ) . Patients transduce donorderived EBVspecific CTLs n't meet release criterion Serologically positive Hepatitis B , C HIV preHSCT Females childbearing age positive pregnancy test Known allergy DMSO</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>Gene Therapy</keyword>
	<keyword>Paediatric</keyword>
	<keyword>B cell Acute Lymphoblastic Leukaemia</keyword>
</DOC>